# Pleryon Pharmaceutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pleryon-pharmaceutics

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.pleryon.com.cn
- Latest round: Series A (Aug 18, 2025)
- Investors on record: 2

## About

Founded in 2016 and based in Shenzhen, China, Pleryon Pharmaceutics is a biotech company that focuses on developing ophthalmic drugs. The founder of the company is Dr. Yu Yu. In August 2025, Pleryon Pharmaceutics raised a Series A funding from new investor Efung Capital.
The company's main products include contact lens lubricant "PN-A001" on the elaSSTM platform and "PN-P001" long-acting anti-VEGF sustained-release gel based on the DynaMCTM platform. The company has a sustained-release drug platform based on microscopic pore size regulation, a polymer drug platform based on modular synthesis, and a nucleic acid delivery platform based on modular non-natural oligomers.
Pleryon Pharmaceutics' revenue generates from out-licensing drug candidates, strategic partnerships, and eventual product commercialization. Additional income may come from veterinary therapeutics, ophthalmic formulations, and platform licensing.

## Funding rounds

- Series A, Aug 18, 2025 — Efung Capital
- Angel, Dec 22, 2020 — Zero2IPO Ventures

## Investors

- Zero2IPO Ventures (https://capitalatlas.ai/funds/zero2ipo-ventures) — Angel
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series A